TRMD 690 Seminar:”Study of maturation status of dengue virus and Dengvaxia recipients in the Philippines”, Yu-Ching Dai, PhD Student

When

02/14/2024    
12:00 PM - 1:00 PM

Where

JABSOM Medical Education Bldg., Rm. 304
651 Ilalo St., Honolulu,, HI

Event Type

In Person and By Zoom

Contact amyount@hawaii.edu for Zoom information

Yu-Ching Dai
Ph.D. Student
Department of Tropical Medicine, Medical Microbiology and Pharmacology
John A. Burns School of Medicine
University of Hawaiʻi at Mānoa


Dengue virus (DENV) is the leading cause of mosquito-borne viral diseases afflicting humans in the tropics and subtropics. Dengvaxia, a chimeric yellow fever tetravalent dengue vaccine, is the first licensed dengue vaccine and is recommended by WHO for baseline DENV-immune individuals only, due to higher risk of severe dengue disease among DENV-naïve recipients. In 2016, a Dengvaxia vaccination campaign was launched in the Philippines with >830,000 children receiving at least one dose without prior serostatus testing. Thousands of DENV-naïve recipients are at high risk during future DENV infection. We previously developed a DENV1-4 nonstructural protein 1 (NS1) IgG ELISA with high sensitivity/specificity and identified baseline DENV-naïve vaccinees from the participants of a fever surveillance program at the Research Institute for Tropical Medicine Philippines. We aimed to further characterize antibody responses among these recipients to improve our uderstanding of immune responses induced by Dengvaxia and future vaccine development. We present our preliminary results of our study, which includes a larger sample size.